{"id":357,"date":"2020-06-28T13:31:01","date_gmt":"2020-06-28T08:01:01","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19\/?page_id=357"},"modified":"2020-06-28T22:50:44","modified_gmt":"2020-06-28T17:20:44","slug":"patents","status":"publish","type":"page","link":"https:\/\/nclinnovations.org\/covid19\/patents\/","title":{"rendered":"Patent Barriers"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\"><strong>Assessment of Patent related barriers for Indian manufacturers<\/strong><\/p>\n<p class=\"\">The TFORD-COVID19-India has commissioned M\/s Gnanlex Hermeneutics Private Limited (Gnanlex) to carry out patent searches and provide their opinion on the patent landscape in India for the drug candidates considered by the TFORD-COVID19-India and also provide insights into the the freedom-to-operate status for Indian manufacturers. Thanks to Gnanlex for providing timely assistance. This section is edited by Dr Vidula Walimbe (TechEx.in at Venture Center).<\/p>\n<p class=\"\"><img decoding=\"async\" loading=\"lazy\" class=\"aligncenter size-medium wp-image-125\" src=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/04\/Tford-Covid-19-2-300x55.jpg\" alt=\"\" width=\"300\" height=\"55\" srcset=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/04\/Tford-Covid-19-2-300x55.jpg 300w, https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/04\/Tford-Covid-19-2-768x142.jpg 768w, https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/04\/Tford-Covid-19-2-250x46.jpg 250w, https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/04\/Tford-Covid-19-2-550x102.jpg 550w, https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/04\/Tford-Covid-19-2-800x148.jpg 800w, https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/04\/Tford-Covid-19-2-974x180.jpg 974w, https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/04\/Tford-Covid-19-2.jpg 990w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/p>\n<p class=\"\"><img decoding=\"async\" loading=\"lazy\" class=\"aligncenter size-medium wp-image-356\" src=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/Gnanlex-300x115.jpg\" alt=\"\" width=\"300\" height=\"115\" srcset=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/Gnanlex-300x115.jpg 300w, https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/Gnanlex-360x139.jpg 360w, https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/Gnanlex-250x96.jpg 250w, https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/Gnanlex.jpg 362w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/p>\n<p class=\"\"><strong>Reports from Gnanlex Hermeneutics Pvt Ltd (<span style=\"color: #ff0000;\">Released on 28 June 2020<\/span>)<\/strong><\/p>\n<ul class=\"\">\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li><strong>Drug Candidates<\/strong>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"list-style-type: none;\">\n<ol>\n<li style=\"text-align: left;\">&nbsp;<a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_ChloroquineJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Chloroquine<\/a><\/li>\n<li style=\"text-align: left;\">&nbsp;<a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_HydroxychloroquineJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Hydroxychloroquine<\/a><\/li>\n<li style=\"text-align: left;\">&nbsp;<a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_RemdesivirJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Remdesivir<\/a>&nbsp;&nbsp;<\/li>\n<li style=\"text-align: left;\">&nbsp;<a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_LopinavirRitonavirJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Lopinavir\/Ritonavir<\/a><\/li>\n<li style=\"text-align: left;\">&nbsp;<a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_FavipiravirJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Favipiravir<\/a><\/li>\n<li style=\"text-align: left;\">&nbsp;<a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_BaloxavirJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Baloxavir Marboxil<\/a><\/li>\n<li style=\"text-align: left;\">&nbsp;<a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_DarunavirJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Darunavir<\/a><\/li>\n<li style=\"text-align: left;\">&nbsp;<a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_RibavirinJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Ribavarin<\/a> + <a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_InterferonJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">IFN-beta<\/a> : <a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_RibavirinInterferonBetaJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Combination<\/a><\/li>\n<li style=\"text-align: left;\">&nbsp;&nbsp;<a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_GalidesivirJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Galidesivir<\/a>&nbsp;&nbsp;<\/li>\n<li style=\"text-align: left;\">&nbsp;<a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_OseltamivirJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Oseltamivir<\/a>&nbsp;&nbsp;<\/li>\n<li style=\"text-align: left;\">&nbsp;<a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_UmifenovirJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Umifenovir<\/a>&nbsp;<\/li>\n<li style=\"text-align: left;\">&nbsp;<a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_CamostatMesylateJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Camostat mesylate<\/a><\/li>\n<li style=\"text-align: left;\">&nbsp;<a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_RuxolitinibJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Ruxolitinib<\/a><\/li>\n<li style=\"text-align: left;\">&nbsp;<a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_InterferonJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">IFN-beta<\/a>&nbsp;&nbsp;<\/li>\n<li style=\"text-align: left;\">&nbsp;<a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_TocilizumabJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Tocilizumab<\/a>&nbsp;<\/li>\n<li style=\"text-align: left;\">&nbsp;Ustekinumab&nbsp;<\/li>\n<li style=\"text-align: left;\">&nbsp;<a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_NigericinJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Nigericin<\/a><\/li>\n<li style=\"text-align: left;\">&nbsp;<a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_TeicoplaninJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Teicoplanin<\/a>&nbsp;&nbsp;<\/li>\n<li style=\"text-align: left;\">&nbsp;<a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_IvermectinJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Ivermectin<\/a><\/li>\n<li>&nbsp;<a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_BaricitinibJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Baricitinib<\/a>&nbsp;<\/li>\n<li>&nbsp;<a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_TofacitinibJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Tofacitinib<\/a>&nbsp;<\/li>\n<li>&nbsp;<a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_DexamethasoneJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Dexamethasone<\/a><\/li>\n<li>&nbsp;<a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_SarilumabJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Sarilumab<\/a><\/li>\n<li>&nbsp;<a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_SepsivacJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Sepsivac<\/a><\/li>\n<li>&nbsp;<a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_UlinastatinJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Ulinastatin<\/a>&nbsp;<\/li>\n<li>&nbsp;<a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_NitazoxanideJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Nitazoxanide<\/a>&nbsp;<\/li>\n<li>&nbsp;Enaxoparin&nbsp;<\/li>\n<li>&nbsp;<a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_FamotidineJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Famotidine<\/a>&nbsp;<\/li>\n<li>&nbsp;ACEi and ARB : <a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_LisinoprilJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Lisinopril<\/a><a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_LosartanJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">| Losartan<\/a><\/li>\n<li>&nbsp;<a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_RecombinantJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">rhACE protein<\/a>&nbsp;<\/li>\n<\/ol>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul class=\"\" style=\"background-color: #ffffff;\">\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"list-style-type: none;\">\n<ul class=\"\">\n<li><strong>Medicinal Herbs&nbsp;<\/strong>\n<ul>\n<li style=\"list-style-type: none;\">\n<ul>\n<li style=\"list-style-type: none;\">\n<ol>\n<li>&nbsp;<a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_TinosporaCordifoliaJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Tinospora cordifolia<\/a>&nbsp;<\/li>\n<li>&nbsp;<a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_GlycyrrhizaGlabraJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Glycyrrhiza glabra<\/a>&nbsp;&nbsp;<\/li>\n<li>&nbsp;<a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_WithiniaSomniferaJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Withania somnifera<\/a>&nbsp;<\/li>\n<li>&nbsp;<a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_ZingiberOfficinaleRoscoeJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Zingiber officinale<\/a>&nbsp;&nbsp;<\/li>\n<li>&nbsp;<a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_AndrographisPaniculataJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Andrographis paniculata<\/a>&nbsp;&nbsp;<\/li>\n<li>&nbsp;<a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_ArtemisiaAnnuaJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Artemisia annua<\/a><\/li>\n<li>&nbsp;<a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_CissampelosPareiraJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Cissampelos pareira<\/a>&nbsp;&nbsp;<\/li>\n<li>&nbsp;<a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_VitisViniferaJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Vitis vinifera<\/a>&nbsp;<\/li>\n<li>&nbsp;<a href=\"https:\/\/nclinnovations.org\/covid19\/wp-content\/uploads\/2020\/06\/IP_MyricaCeriferaJune2020.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Myrica cerifera<\/a>&nbsp;<\/li>\n<\/ol>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p class=\"\">&nbsp;<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Assessment of Patent related barriers for Indian manufacturers The TFORD-COVID19-India has commissioned M\/s Gnanlex Hermeneutics Private Limited (Gnanlex) to carry out patent searches and provide their opinion on the patent landscape in India for the drug candidates considered by the TFORD-COVID19-India and also provide insights into the the freedom-to-operate status for Indian manufacturers. Thanks to &hellip; <a href=\"https:\/\/nclinnovations.org\/covid19\/patents\/\" class=\"more-link\">Continue reading <span class=\"screen-reader-text\">Patent Barriers<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"template\/page\/fullwidth.php","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19\/wp-json\/wp\/v2\/pages\/357"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19\/wp-json\/wp\/v2\/comments?post=357"}],"version-history":[{"count":10,"href":"https:\/\/nclinnovations.org\/covid19\/wp-json\/wp\/v2\/pages\/357\/revisions"}],"predecessor-version":[{"id":418,"href":"https:\/\/nclinnovations.org\/covid19\/wp-json\/wp\/v2\/pages\/357\/revisions\/418"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19\/wp-json\/wp\/v2\/media?parent=357"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}